Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 23, Issue 15, Pages 4434-4441Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2015.06.018
Keywords
DYRK1; Kinase inhibitor; Structural modification; Docking model; Dibenzofuran; Adipogenesis
Funding
- Japan Science and Technology Agency (J-AMP) [10103930]
- Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (KAKENHI) [24241076]
- Platform for Drug Discovery, Informatics, and Structural Life Science of MEXT, Japan
- Grants-in-Aid for Scientific Research [21249013, 15H02505, 15H05721] Funding Source: KAKEN
Ask authors/readers for more resources
Dysregulation of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) has been demonstrated in several pathological conditions, including Alzheimer's disease and cancer progression. It has been recently reported that a gain of function-mutation in the human DYRK1B gene exacerbates metabolic syndrome by enhancing obesity. In the previous study, we developed an inhibitor of DYRK family kinases (INDY) and demonstrated that INDY suppresses the pathological phenotypes induced by overexpression of DYRK1A or DYRK1B in cellular and animal models. In this study, we designed and synthesized a novel inhibitor of DYRK family kinases based on the crystal structure of the DYRK1A/INDY complex by replacing the phenol group of INDY with dibenzofuran to produce a derivative, named BINDY. This compound exhibited potent and selective inhibitory activity toward DYRK family kinases in an in vitro assay. Furthermore, treatment of 3T3-L1 pre-adipocytes with BINDY hampered adipogenesis by suppressing gene expression of the critical transcription factors PPARc and C/EBPa. This study indicates the possibility of BINDY as a potential drug for metabolic syndrome. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available